|
|
|
|
| LEADER |
01686nam a2200313 u 4500 |
| 001 |
EB001999457 |
| 003 |
EBX01000000000000001162358 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Fluocinolone acetonide (Iluvien -- Knight Therapeutics Inc.)
|h Elektronische Ressource
|b indication : diabetic macular edema
|
| 246 |
3 |
1 |
|a Fluocinolone acetonide (Iluvien -- Knight Therapeutics Inc.)
|
| 246 |
3 |
1 |
|a Drug reimbursement recommendation Fluocinolone acetonide (Iluvien)
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c September 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (8 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Insurance, Health, Reimbursement
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Macular Edema / drug therapy
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Intravitreal Injections
|
| 653 |
|
|
|a Fluocinolone Acetonide / therapeutic use
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK551888
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Recommendation: The CADTH Canadian Drug Expert Committee (CDEC) recommends that the fluocinolone acetonide intravitreal implant should not be reimbursed for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure
|